Cognitive fog doesn't lift when depression does — for millions of people with recurrent depressive disorder, memory gaps and slowed thinking persist long after mood normalizes. That residual burden raises relapse risk and undermines daily functioning, yet no approved treatment specifically targets post-depressive cognitive deficits. A double-blind, placebo-controlled trial published in Psychological Medicine now offers a mechanistically novel answer: stimulating serotonin-4 receptors may directly sharpen cognition, independent of mood improvement.
Fifty adults in full remission from recurrent depression (minimum two prior episodes) were randomized to either prucalopride — a selective 5-HT4 receptor agonist approved for chronic constipation — or placebo for seven to ten days. Prucalopride, titrated from 1 mg to 2 mg daily, produced significant gains on auditory verbal learning (word recall), faster response times on a complex working memory task without accuracy trade-offs, and improved recognition of rapidly presented emotional facial expressions. A composite analysis across non-emotional cognitive tasks confirmed that prucalopride participants were both faster and more accurate post-intervention relative to their baseline, while placebo recipients showed no comparable shift. Crucially, these gains were independent of participants' baseline mood scores, ruling out an indirect antidepressant mechanism.
This finding is meaningful because it dissociates the cognitive and affective channels of serotonin signaling. Most antidepressants act primarily on 5-HT1A or serotonin-reuptake mechanisms, and their cognitive benefits — where they exist — are modest and mood-mediated. The 5-HT4 pathway, by contrast, is enriched in hippocampal and prefrontal circuits implicated in neuroplasticity, and animal work has shown 5-HT4 agonism upregulates BDNF and promotes synaptogenesis. The current human data align with that preclinical story. Key caveats: the sample is small (n = 50), the intervention window is very short (under two weeks), the population is highly specific (remitted but recurrent depression), and longer-term cognitive durability remains untested. Whether prucalopride's gastrointestinal profile limits CNS-focused dosing regimens is also unresolved. This is an early but genuinely intriguing signal — more confirmatory than paradigm-shifting yet, but one that positions 5-HT4 agonism as a credible target for future cognitive-enhancement trials in mood disorder populations.